by Alexander Fenkiw | Nov 25, 2025 | diga-whitepaper, Unkategorisiert
What is the point of a DiGA if it does not improve patients’ lives? There is none! This is why DiGAs are only justified when their positive supply effect has been proven. Only then do you have a chance of being permanently included in the BfArM register....
by Alexander Fenkiw | Jan 9, 2025 | medical-software-whitepaper
At the beginning of the development of a software medical device, the central question is: Which risk class applies to my product? Risk classification has serious implications and significantly influences the cost and time frame of product development. In extreme...
by Alexander Fenkiw | Sep 10, 2024 | medical-software-whitepaper
How do I actually decide whether my product is a medical device? Where do I start when I want to determine its risk class? And what statements can I use to promote my product in the end? The answers to these and many other questions can be answered on the basis of...
by Alexander Fenkiw | Dec 30, 2022 | medical-software-whitepaper, Unkategorisiert
If you are developing software that qualifies as a medical device under the Medical Device Regulation (MDR), validation is one of the most critical issues. Successful validation of your software is an absolute prerequisite for bringing your medical device to market....
by Alexander Fenkiw | May 3, 2022 | diga-whitepaper
Attention manufacturers of electronic aids, implants and DiGA! From mid-2024, a new legal requirement will apply to improve interoperability between medical devices and digital health applications (DiGA) approved by the BfArM: §374a SGB V Specifically, this involves...